Selective inhibition of SIN3 corepressor with avermectins as a novel therapeutic strategy in triple negative breast cancer

Triple negative breast cancers (TNBC) lacking estrogen, progesterone and HER2 receptors account for 10–20% of breast cancer and are indicative of poor prognosis. The development of effective treatment strategies therefore represents a pressing unmet clinical need. We previously identified a molecula...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Mol Cancer Ther
Auteurs principaux: Kwon, Yeon-Jin, Petrie, Kevin, Leibovitch, Boris A., Zeng, Lei, Mezei, Mihaly, Howell, Louise, Gil, Veronica, Christova, Rossitza, Bansal, Nidhi, Yang, Shuai, Sharma, Rajal, Ariztia, Edgardo V., Frankum, Jessica, Brough, Rachel, Sbirkov, Yordan, Ashworth, Alan, Lord, Christopher J., Zelent, Arthur, Farias, Eduardo, Zhou, Ming-Ming, Waxman, Samuel
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4529816/
https://ncbi.nlm.nih.gov/pubmed/26078298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0980-T
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires